We reported (PLoS One 6 (12):e28670, 2011) that the activation of c-Met signaling in RANKL-overexpressing bone metastatic LNCaP cell and xenograft models increased expression of RANK, RANKL, c-Met, and phosphorylated c-Met, and mediated downstream signaling. We confirmed the significance of the RANK-mediated signaling network in castration resistant clinical human prostate cancer (PC) tissues. In this report, we used a multispectral quantum dot labeling technique to label six RANK and c-Met convergent signaling pathway mediators simultaneously in formalin fixed paraffin embedded (FFPE) tissue specimens, quantify the intensity of each expression at the sub-cellular level, and investigated their potential utility as predictors of patient survival in Caucasian-American, African-American and Chinese men. We found that RANKL and neuropilin-1 (NRP-1) expression predicts survival of Caucasian-Americans with PC. A Gleason score ≥8 combined with nuclear p-c-Met expression predicts survival in African-American PC patients. Neuropilin-1, p-NF-κB p65 and VEGF are predictors for the overall survival of Chinese men with PC. These results collectively support interracial differences in cell signaling networks that can predict the survival of PC patients.
References
[1]
Grivas PD, Robins DM, Hussain M (2013) Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer. Crit Rev Oncol Hematol 85: 82–93.
[2]
Kachroo N, Gnanapragasam VJ (2013) The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review. J Cancer Res Clin Oncol 139: 1–24.
[3]
Tran PT, Hales RK, Zeng J, Aziz K, Salih T, et al. (2012) Tissue biomarkers for prostate cancer radiation therapy. Curr Mol Med 12: 772–787.
[4]
Koeneman KS, Yeung F, Chung LW (1999) Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39: 246–261.
[5]
Josson S, Matsuoka Y, Chung LW, Zhau HE, Wang R (2010) Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol 21: 26–32.
[6]
Hu P, Chu GC, Zhu G, Yang H, Luthringer D, et al. (2011) Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. PLoS One 6: e28670.
[7]
Lue HW, Yang X, Wang R, Qian W, Xu RZ, et al. (2011) LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling. PLoS One 6: e27720.
[8]
Odero-Marah VA, Wang R, Chu G, Zayzafoon M, Xu J, et al. (2008) Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res 18: 858–870.
[9]
Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, et al. (2006) Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 66: 1664–1673.
[10]
Zhang S, Wang X, Iqbal S, Wang Y, Osunkoya AO, et al. (2013) Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition. J Biol Chem 288: 1469–1479.
[11]
Zhang S, Wang X, Osunkoya AO, Iqbal S, Wang Y, et al. (2011) EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis. Oncogene 30: 4941–4952.
[12]
Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, et al. (2008) Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis 25: 601–610.
[13]
Kyrgidis A, Tzellos TG (2012) Denosumab in castration-resistant prostate cancer. Lancet 379: e50; author reply e50–51.
[14]
Lee HJ, Gallego-Ortega D, Ledger A, Schramek D, Joshi P, et al. (2013) Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells. Development 140: 1397–1401.
[15]
Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, et al. (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468: 98–102.
[16]
Chu GCY, Zhau HE, Wang R, Rogatko A, Feng X, et al.. (2013) Autocrine/paracrine RANKL-RANK signaling promotes cancer bone metastasis and establishes premetastatic niche recruiting bystander cancer cells to participate in the metastatic process. American Association for Cancer Research, 2013 Annual Meeting. Walter E. Washington Convention Center, Washington, DC. #3942.
[17]
Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29: 10–14.
[18]
Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, et al . 1998) Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51: 161–167.
[19]
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604–4613.
[20]
Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735–745.
[21]
Whitaker GB, Limberg BJ, Rosenbaum JS (2001) Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF (165) and VEGF (121). J Biol Chem 276: 25520–25531.
[22]
Talagas M, Uguen A, Garlantezec R, Fournier G, Doucet L, et al. (2013) VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer. Anticancer Res 33: 2065–2075.
[23]
Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, et al. (2010) Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 9: 9.
[24]
Hatcher D, Daniels G, Osman I, Lee P (2009) Molecular mechanisms involving prostate cancer racial disparity. Am J Transl Res 1: 235–248.
[25]
Thatai LC, Banerjee M, Lai Z, Vaishampayan U (2004) Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer. Urology 64: 738–743.
[26]
Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, et al. (2007) Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 13: 3796–3802.
[27]
Zhau HE, Zhao LS, Chen BQ, Kojima M (1997) Interracial comparative study of prostate cancer in the United States, China, and Japan. J Cell Biochem Suppl 28–29: 182–185.
[28]
Zhau HE, Zhao LS, Chung LW, Chen BQ, Troncoso P, et al. (1995) Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations. Urol Oncol 1: 51–63.
